Literature DB >> 28127140

Dasatinib-induced chylothorax in chronic myeloid leukemia.

Zulfiqar Qutrio Baloch1, Shabber Agha Abbas1, Hammad Bhatti1, Yvonne Braver1, Sayed K Ali1.   

Abstract

Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.

Entities:  

Year:  2017        PMID： 28127140      PMCID： PMC5242121          DOI： 10.1080/08998280.2017.11929535

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  19 in total

Review 1.  Src family tyrosine kinases and growth factor signaling.

Authors:  C L Abram; S A Courtneidge
Journal:  Exp Cell Res       Date:  2000-01-10       Impact factor: 3.905

2.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

3.  Management of thoracic duct injury associated with fracture-dislocation of the spine following blunt trauma.

Authors:  M L Silen; T R Weber
Journal:  J Trauma       Date:  1995-12

4.  Chylothorax and chylopericardium: a complication of a central venous catheter.

Authors:  E Kurekci; R Kaye; M Koehler
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

Review 5.  Cellular functions regulated by Src family kinases.

Authors:  S M Thomas; J S Brugge
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

6.  The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo.

Authors:  F Luton; M Vergés; J P Vaerman; M Sudol; K E Mostov
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

Review 7.  Pleural effusions due to dasatinib.

Authors:  Anupama G Brixey; Richard W Light
Journal:  Curr Opin Pulm Med       Date:  2010-07       Impact factor: 3.155

8.  Isolated thoracic duct injury after penetrating chest trauma.

Authors:  M G Worthington; M de Groot; A J Gunning; U O von Oppell
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

9.  A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src.

Authors:  Neil O Carragher; M Andrew Westhoff; Valerie J Fincham; Michael D Schaller; Margaret C Frame
Journal:  Curr Biol       Date:  2003-08-19       Impact factor: 10.834

10.  The lipoprotein profile of chylous and nonchylous pleural effusions.

Authors:  B A Staats; R D Ellefson; L L Budahn; D E Dines; U B Prakash; K Offord
Journal:  Mayo Clin Proc       Date:  1980-11       Impact factor: 7.616
View more
  6 in total

1.  Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.

Authors:  Theresa Paul; Anil Yousaf Ellahie; Yazan Salah Almohtasib; Urshita Sinha; Halima El Omri
Journal:  EJHaem       Date:  2021-05-18

2.  Chylothorax: complication attributed to dasatinib use.

Authors:  Abdullah Al-Abcha; Mian Harris Iftikhar; Fawzi Abu Rous; Heather Laird-Fick
Journal:  BMJ Case Rep       Date:  2019-12-16

3.  Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.

Authors:  Chao-Chin Hsu; Jui-Feng Hsu; Kuan-Li Wu
Journal:  Respirol Case Rep       Date:  2021-05-07

Review 4.  Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan".

Authors:  Hisashi Sasaki; Yoshifumi Kimizuka; Hiraku Ogata; Yosuke Okada; Shinichiro Ota; Tomoya Sano; Chie Watanabe; Yohei Maki; Takayuki Yamamoto; Yoichi Tagami; Jun Miyata; Nobuyoshi Hayashi; Yuji Fujikura; Akihiko Kawana
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

Review 5.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

6.  Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib.

Authors:  Syed Alishan Nasir; Hugo Calavia Liano; Christopher Manfredi
Journal:  Cureus       Date:  2022-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.